Compare BY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | FTRE |
|---|---|---|
| Founded | 1914 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2017 | 2023 |
| Metric | BY | FTRE |
|---|---|---|
| Price | $32.51 | $10.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $33.50 | $15.50 |
| AVG Volume (30 Days) | 157.7K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | N/A | ★ $2,696,400,000.00 |
| Revenue This Year | $17.06 | $3.21 |
| Revenue Next Year | $2.84 | $0.25 |
| P/E Ratio | $15.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.63 | $3.97 |
| 52 Week High | $33.89 | $18.67 |
| Indicator | BY | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 34.60 |
| Support Level | $32.00 | $9.35 |
| Resistance Level | $33.89 | $11.46 |
| Average True Range (ATR) | 0.83 | 1.19 |
| MACD | -0.18 | -0.11 |
| Stochastic Oscillator | 43.46 | 29.16 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.